ATE478688T1 - Verbindungen für den transfer von oligonukleotiden - Google Patents
Verbindungen für den transfer von oligonukleotidenInfo
- Publication number
- ATE478688T1 ATE478688T1 AT01938732T AT01938732T ATE478688T1 AT E478688 T1 ATE478688 T1 AT E478688T1 AT 01938732 T AT01938732 T AT 01938732T AT 01938732 T AT01938732 T AT 01938732T AT E478688 T1 ATE478688 T1 AT E478688T1
- Authority
- AT
- Austria
- Prior art keywords
- oligonucleotides
- compounds
- transfer
- collagen
- preparations
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 102000008186 Collagen Human genes 0.000 abstract 1
- 108010035532 Collagen Proteins 0.000 abstract 1
- 210000004102 animal cell Anatomy 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 229920001436 collagen Polymers 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000184502 | 2000-06-20 | ||
| PCT/JP2001/005195 WO2001097857A1 (fr) | 2000-06-20 | 2001-06-19 | Preparations destinees au transfert d'oligonucleotides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE478688T1 true ATE478688T1 (de) | 2010-09-15 |
Family
ID=18684937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01938732T ATE478688T1 (de) | 2000-06-20 | 2001-06-19 | Verbindungen für den transfer von oligonukleotiden |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20040052840A1 (de) |
| EP (1) | EP1295611B1 (de) |
| JP (1) | JP5118285B2 (de) |
| AT (1) | ATE478688T1 (de) |
| AU (1) | AU2001264317A1 (de) |
| DE (1) | DE60142899D1 (de) |
| DK (1) | DK1295611T3 (de) |
| ES (1) | ES2349137T3 (de) |
| PT (1) | PT1295611E (de) |
| WO (1) | WO2001097857A1 (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW586934B (en) * | 1997-05-19 | 2004-05-11 | Sumitomo Pharma | Immunopotentiating composition |
| EP1295611B1 (de) * | 2000-06-20 | 2010-08-25 | Dainippon Sumitomo Pharma Co., Ltd. | Verbindungen für den transfer von oligonukleotiden |
| ATE429930T1 (de) | 2001-06-20 | 2009-05-15 | Dainippon Sumitomo Pharma Co | Verfahren zur förderung des nukleinsäuretransfers |
| US20100104631A1 (en) * | 2001-08-13 | 2010-04-29 | Lipella Pharmaceuticals Inc. | Method of treatment for bladder dysfunction |
| AU2003264507A1 (en) * | 2002-09-20 | 2004-04-08 | Koken Co., Ltd. | Site-specific gene conversion promoter and gene therapeutic |
| EP1696034A4 (de) * | 2003-12-19 | 2006-12-27 | Dainippon Sumitomo Pharma Co | Neues verfahren zum nukleinsäuretransfer |
| US20090062184A1 (en) * | 2005-03-24 | 2009-03-05 | Dainippon Sumitomo Pharma Co., Ltd. | Fine particulate preparation comprising complex of nucleic acid molecule and collagen |
| US7838502B2 (en) * | 2005-05-06 | 2010-11-23 | University Of Massachusetts Medical School | Compositions and methods to modulate H. influenzae pathogenesis |
| WO2006126600A1 (ja) * | 2005-05-25 | 2006-11-30 | National University Corporation Nagoya Universtiy | 血管閉塞性疾患用医薬組成物 |
| KR100777249B1 (ko) | 2006-02-14 | 2007-11-28 | (주)바이오니아 | 건조 올리고뉴클레오티드 조성물 및 이의 제조 방법 |
| WO2010078403A2 (en) * | 2008-12-30 | 2010-07-08 | Lipella Pharmaceuticals Inc. | Methods and compositions for diagnosing urological disorders |
| FR3066115B1 (fr) | 2017-05-10 | 2019-06-28 | Universite de Bordeaux | Comprimes de vecteurs d'acides nucleiques |
| MX2021015539A (es) * | 2019-07-02 | 2022-02-10 | Hoffmann La Roche | Proceso para la preparacion de productos del tipo de alta hidrofilia con humedad controlada. |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5115094B2 (de) * | 1972-11-01 | 1976-05-14 | ||
| US5069936A (en) * | 1987-06-25 | 1991-12-03 | Yen Richard C K | Manufacturing protein microspheres |
| US5078997A (en) * | 1988-07-13 | 1992-01-07 | Cetus Corporation | Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers |
| US5098890A (en) * | 1988-11-07 | 1992-03-24 | Temple University-Of The Commonwealth System Of Higher Education | Antisence oligonucleotides to c-myb proto-oncogene and uses thereof |
| US5614587A (en) * | 1988-11-21 | 1997-03-25 | Collagen Corporation | Collagen-based bioadhesive compositions |
| US5936035A (en) * | 1988-11-21 | 1999-08-10 | Cohesion Technologies, Inc. | Biocompatible adhesive compositions |
| JP3187410B2 (ja) * | 1989-08-10 | 2001-07-11 | 住友製薬株式会社 | 脳内投与用徐放性製剤 |
| US5542935A (en) * | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
| US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| FR2694895B1 (fr) * | 1992-08-20 | 1994-11-10 | Coletica | Procédé de fabrication de microparticules en émulsion par modification de la composition chimique de la phase dispersée après émulsification. |
| US5646042A (en) * | 1992-08-26 | 1997-07-08 | Ribozyme Pharmaceuticals, Inc. | C-myb targeted ribozymes |
| WO1994028014A2 (en) * | 1993-05-28 | 1994-12-08 | Chiron Corporation | Peptide inhibitors of urokinase receptor activity |
| ATE197124T1 (de) * | 1993-09-09 | 2000-11-15 | Schering Ag | Wirkstoffe und gas enthaltende mikropartikel |
| CA2140053C (en) * | 1994-02-09 | 2000-04-04 | Joel S. Rosenblatt | Collagen-based injectable drug delivery system and its use |
| US5942496A (en) * | 1994-02-18 | 1999-08-24 | The Regent Of The University Of Michigan | Methods and compositions for multiple gene transfer into bone cells |
| US5583034A (en) * | 1994-02-22 | 1996-12-10 | La Jolla Institute For Allergy And Immunology | Enhancement of adoptosis using antisense oligonucleotides |
| US5844107A (en) * | 1994-03-23 | 1998-12-01 | Case Western Reserve University | Compacted nucleic acids and their delivery to cells |
| US5563255A (en) * | 1994-05-31 | 1996-10-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
| EP0769063A1 (de) * | 1994-06-27 | 1997-04-23 | The Johns Hopkins University | Gezielte freigabe genetischen materials |
| EP0844004B1 (de) * | 1995-07-03 | 2007-09-12 | Koken Co., Ltd. | Atelocollagen enthaltende gen-zusammensetzungen |
| US6998268B2 (en) * | 1995-07-03 | 2006-02-14 | Dainippon Sumitomo Pharma Co. Ltd. | Gene preparations |
| JP3867160B2 (ja) * | 1995-07-03 | 2007-01-10 | 大日本住友製薬株式会社 | 遺伝子製剤 |
| MY134778A (en) * | 1995-10-23 | 2007-12-31 | Hyal Pharmaceutical Australia Ltd | Hyaluronic acid as dna carrier for gene therapy and vegf antisense dna to treat abnormal retinal vascularization |
| PT876165E (pt) * | 1995-12-18 | 2006-10-31 | Angiotech Biomaterials Corp | Composicoes de polimeros reticulados e processos para a sua utilizacao |
| CA2248538A1 (en) * | 1996-03-14 | 1997-09-18 | The Immune Response Corporation | Targeted delivery of genes encoding interferon |
| US6133437A (en) * | 1997-02-13 | 2000-10-17 | Apoptogen, Inc. | Modulation of IAPs for the treatment of proliferative diseases |
| US5874006A (en) * | 1996-10-31 | 1999-02-23 | Matrix Pharmaceutical, Inc. | Aseptic collagen concentration process |
| US6042820A (en) * | 1996-12-20 | 2000-03-28 | Connaught Laboratories Limited | Biodegradable copolymer containing α-hydroxy acid and α-amino acid units |
| US6218112B1 (en) * | 1996-12-23 | 2001-04-17 | Cobra Therapeutics Limited | Optimization of gene delivery and gene delivery system |
| WO1998030575A1 (en) * | 1997-01-08 | 1998-07-16 | Proligo Llc | Bioconjugation of macromolecules |
| US6524613B1 (en) * | 1997-04-30 | 2003-02-25 | Regents Of The University Of Minnesota | Hepatocellular chimeraplasty |
| EP1054694A2 (de) * | 1998-02-13 | 2000-11-29 | Selective Genetics, Inc. | Gleichzeitige strömungsdurchmischung zur herstellung von zusammensetzungen, die gentherapievektoren enthalten |
| KR100600464B1 (ko) * | 1998-05-22 | 2006-07-13 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 안정한 유전자 제제 |
| AU2001251115A1 (en) * | 2000-03-31 | 2001-10-15 | Trustees Of Boston University | Use of locally applied dna fragments |
| EP1295611B1 (de) * | 2000-06-20 | 2010-08-25 | Dainippon Sumitomo Pharma Co., Ltd. | Verbindungen für den transfer von oligonukleotiden |
| JP2002325572A (ja) * | 2000-12-25 | 2002-11-12 | Univ Osaka | 外来物質の導入方法 |
| ATE429930T1 (de) * | 2001-06-20 | 2009-05-15 | Dainippon Sumitomo Pharma Co | Verfahren zur förderung des nukleinsäuretransfers |
| US7148342B2 (en) * | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
| WO2004022075A1 (en) * | 2002-09-04 | 2004-03-18 | Novartis Ag | Treatment of neurological disorders by dsrna adminitration |
| AU2003264507A1 (en) * | 2002-09-20 | 2004-04-08 | Koken Co., Ltd. | Site-specific gene conversion promoter and gene therapeutic |
| EP1562970A4 (de) * | 2002-11-01 | 2006-04-12 | Univ Pennsylvania | ZUSAMMENSETZUNGEN UND VERFAHREN ZUR siRNA-HEMMUNG VON HIF-1 ALPHA |
| ATE477337T1 (de) * | 2003-01-16 | 2010-08-15 | Univ Pennsylvania | Zusammensetzungen und verfahren zur sirna-hemmung von icam-1 |
| US8227434B1 (en) * | 2003-11-04 | 2012-07-24 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Materials and methods for treating oncological disorders |
| AU2005216298B2 (en) * | 2004-02-26 | 2010-09-02 | Baylor Research Institute | Compositions and methods for the systemic treatment of arthritis |
| AU2005288522B2 (en) * | 2004-09-28 | 2012-06-28 | Quark Pharmaceuticals, Inc. | Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases |
| US8187823B2 (en) * | 2004-10-22 | 2012-05-29 | UNIVERSITé LAVAL | Modulation of neuroglia-derived BDNF in the treatment and prevention of pain |
| US7585848B2 (en) * | 2005-01-11 | 2009-09-08 | Rush University Medical Center | Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc |
| WO2007082899A1 (en) * | 2006-01-17 | 2007-07-26 | Vib Vzw | Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration |
| EP2047864B1 (de) * | 2006-06-16 | 2017-04-05 | Taisho Pharmaceutical Co., Ltd. | Verwendung von rpn2-gen-expressionshemmer |
| RU2553561C2 (ru) * | 2006-07-21 | 2015-06-20 | Сайленс Терапьютикс Аг | Средства ингибирования экспрессии протеинкиназы 3 |
| US7825101B2 (en) * | 2006-08-30 | 2010-11-02 | The Board Of Trustees Of The University Of Illinois | Modulation of MLCK-L expression and uses thereof |
| AU2007302803A1 (en) * | 2006-10-02 | 2008-04-10 | Aprea Ab | RNA interference against Wrap53 to treat hyperproliferative diseases |
| US7812002B2 (en) * | 2007-03-21 | 2010-10-12 | Quark Pharmaceuticals, Inc. | Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer |
| WO2011069155A1 (en) * | 2009-12-04 | 2011-06-09 | Opko Ophthalmics, Llc | Compositions and methods for inhibition of vegf |
-
2001
- 2001-06-19 EP EP01938732A patent/EP1295611B1/de not_active Expired - Lifetime
- 2001-06-19 US US10/311,621 patent/US20040052840A1/en not_active Abandoned
- 2001-06-19 DK DK01938732.3T patent/DK1295611T3/da active
- 2001-06-19 AU AU2001264317A patent/AU2001264317A1/en not_active Abandoned
- 2001-06-19 WO PCT/JP2001/005195 patent/WO2001097857A1/ja not_active Ceased
- 2001-06-19 AT AT01938732T patent/ATE478688T1/de active
- 2001-06-19 PT PT01938732T patent/PT1295611E/pt unknown
- 2001-06-19 ES ES01938732T patent/ES2349137T3/es not_active Expired - Lifetime
- 2001-06-19 DE DE60142899T patent/DE60142899D1/de not_active Expired - Lifetime
- 2001-06-19 JP JP2002503340A patent/JP5118285B2/ja not_active Expired - Fee Related
-
2009
- 2009-06-17 US US12/486,703 patent/US20090258933A1/en not_active Abandoned
-
2010
- 2010-10-13 US US12/904,054 patent/US20110028535A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20040052840A1 (en) | 2004-03-18 |
| AU2001264317A1 (en) | 2002-01-02 |
| JP5118285B2 (ja) | 2013-01-16 |
| EP1295611B1 (de) | 2010-08-25 |
| DE60142899D1 (de) | 2010-10-07 |
| ES2349137T3 (es) | 2010-12-28 |
| US20110028535A1 (en) | 2011-02-03 |
| US20090258933A1 (en) | 2009-10-15 |
| DK1295611T3 (da) | 2010-10-04 |
| EP1295611A1 (de) | 2003-03-26 |
| WO2001097857A1 (fr) | 2001-12-27 |
| EP1295611A4 (de) | 2009-07-08 |
| PT1295611E (pt) | 2010-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123084T1 (el) | Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι | |
| EP1325019A4 (de) | Antisense-modulation der clusterinexpression | |
| ATE305788T1 (de) | (s,s)-reboxetin zur behandlung von inkontinenz | |
| TW200502385A (en) | Modulation of forkhead box o1a expression | |
| EP1248794A4 (de) | Antisens-modulierung der smad7 expression | |
| EP1417351A4 (de) | Antisense-modulation der expression von apolipoprotein(a) | |
| DE60118604D1 (de) | Photosensibilisator-enthaltende lagerungslösung zur inaktivierung von biologischen verunreinigungen | |
| DE60142899D1 (de) | Verbindungen für den transfer von oligonukleotiden | |
| WO2004030750A8 (en) | Antisense modulation of farnesoid x receptor expression | |
| DE3782214D1 (de) | Mittel zur behandlung des scheidenmilieus. | |
| EP1648910A4 (de) | Antisense-modulation der expression von stearoyl coa desaturase | |
| WO2001029175A3 (en) | Antisense modulation of fra-1 expression | |
| EP1218398A4 (de) | Antisense-modulation von pi3-kinase p110 beta-expression | |
| EP1250347A4 (de) | Antisense modulation der akt-3 expression | |
| DE50009838D1 (de) | Humanes antibiotisches protein | |
| ATE344662T1 (de) | Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen | |
| DK1359943T3 (da) | Biotinderivater og deres konjugater med chelateringsmidler | |
| PT1165444E (pt) | Utilizacao de derivados de porfirina em aquarios | |
| WO2002041836A3 (en) | Antisense modulation of src-1 expression | |
| WO2002040637A3 (en) | Antisense modulation of pi3k p85 expression | |
| EP1373291A4 (de) | Antisense-modulierung der recql4 expression | |
| UA32241A (uk) | Спосіб лікування запалювальних процесів у експериментальних тварин | |
| ZA200103603B (en) | Treatment of animal hides. | |
| UA38418A (uk) | Засіб для стимуляції регенеративних процесів в інсулінпродукуючому апараті підшлункової залози | |
| WO2002044325A3 (en) | Antisense modulation of src-1 expression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1295611 Country of ref document: EP |